{"protocolSection":{"identificationModule":{"nctId":"NCT03357133","orgStudyIdInfo":{"id":"2017032"},"organization":{"fullName":"Capital Medical University","class":"OTHER"},"briefTitle":"Tirofiban for Patients Treated With Alteplase","officialTitle":"A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Early Administration of Tirofiban in Acute Ischemic Stroke Patients Treated With Intravenous Alteplase Thrombolysis","acronym":"MR TEA"},"statusModule":{"statusVerifiedDate":"2020-09","overallStatus":"TERMINATED","whyStopped":"The number and speed of enrollment were significantly less than expected.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-12-16","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-06-01","type":"ACTUAL"},"completionDateStruct":{"date":"2020-08-31","type":"ACTUAL"},"studyFirstSubmitDate":"2017-11-23","studyFirstSubmitQcDate":"2017-11-23","studyFirstPostDateStruct":{"date":"2017-11-29","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-09-06","lastUpdatePostDateStruct":{"date":"2020-09-09","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Ji Xunming,MD,PhD","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Capital Medical University"},"leadSponsor":{"name":"Capital Medical University","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"After intravenous thrombolysis, the overall recanalization rate is 46%, and recclusion after initial recanalization occurs in 14-34%. In the MR TEA, the investigators compared the effects of administration of tirofiban in acute ischemic stroke patients treated with intravenous alteplase thrombolysis with alteplase alone."},"conditionsModule":{"conditions":["Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":30,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Tirofiban and alteplase","type":"EXPERIMENTAL","interventionNames":["Drug: Tirofiban"]},{"label":"Alteplase","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Alteplase"]}],"interventions":[{"type":"DRUG","name":"Tirofiban","description":"Tirofiban Injection after the alteplase intravenous thrombolysis","armGroupLabels":["Tirofiban and alteplase"]},{"type":"DRUG","name":"Alteplase","description":"Only alteplase intravenous thrombolysis","armGroupLabels":["Alteplase"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The rate of favorable outcome","description":"favorable outcome was defined as a score of 0, or 1 on the modified Rankin scale","timeFrame":"90 days"}],"secondaryOutcomes":[{"measure":"mRS ≤2","timeFrame":"90 days"},{"measure":"NIHSS score","timeFrame":"7 days"},{"measure":"Deterioration after improvement","timeFrame":"24 hours"},{"measure":"Final infarct size","timeFrame":"24 hours"}],"otherOutcomes":[{"measure":"Symptomatic intracranial hemorrhage","timeFrame":"7 days or discharge"},{"measure":"Severe systemic bleeding","timeFrame":"7 days or discharge"},{"measure":"Stroke-related death","timeFrame":"90 days"},{"measure":"Death form any cause","timeFrame":"90 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥18\n* Ischemic stroke symptom with onset ≤4.5 hours treated with IV rt-PA according with local guidelines.\n* 6≤ NIHSS ≤20 before IV tPA, or NIHSS \\>20 but decrease ≥ 8 after IV rt-PA.\n* ≥ 4 point total NIHSS or ≥ 2 point in one NIHSS category during and after the IV rt-PA compared to immediately before worsening, an emergency CT scan should be performed to exclude intracranial hemorrhage\n* Patients or their legally acceptable representative agreed to the treatment and signed the informed consent form\n\nExclusion Criteria:\n\n* Patients whom the treating physician is planning to treat with mechanical thrombectomy or other endovascular procedure (e.g. Intra-arterial thrombolysis) according with local guidelines.\n* Patients had used antiplatelet therapy in the past 5 days before the stroke.\n* Patients had used anticoagulant therapy in the past 5 days before the stroke.\n* Scheduled for surgery or interventional treatment requiring study drug cessation.\n* CT scan finding of hypoattenuation involving ≥1/3 of the MCA territory.\n* Any evidence of clinically significant bleeding ,or known coagulopathy.\n* Renal insufficiency (creatinine clearance rate \\<30ml/min)\n* Hepatic dysfunction (ALT \\>2 folds of Upper limit of normal value or AST\\>2 folds of Upper limit of normal value).\n* Pre-existing disability with ≥ mRS 2.\n* Known allergic to tirofiban or other glycoprotein IIb/IIIa antagonist.\n* Severe non-cerebrovascular disease with life expectancy \\<3 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Suzhou Municipal Hoapital","city":"Suzhou","state":"An Hui","country":"China","geoPoint":{"lat":31.30408,"lon":120.59538}},{"facility":"Xuanwu Hospital, Capital Medical University","city":"Beijing","state":"Beijing","zip":"100053","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"The Central Hospital of Luohe City","city":"Luohe","state":"Henan","country":"China","geoPoint":{"lat":33.56394,"lon":114.04272}},{"facility":"Luzhou People's Hospital","city":"Luzhou","state":"Sichuan","country":"China"},{"facility":"Xiangtan Central Hospital","city":"Xiangtan","country":"China","geoPoint":{"lat":27.85,"lon":112.9}},{"facility":"The Fifth Affiliated Hospital of Zhengzhou University","city":"Zhengzhou","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"The First Affiliated Hospital of Zhengzhou University","city":"Zhengzhou","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000010959","term":"Tissue Plasminogen Activator"},{"id":"D000077466","term":"Tirofiban"}],"ancestors":[{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"}],"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","asFound":"Patient Reported Outcomes","relevance":"HIGH"},{"id":"M1807","name":"Tirofiban","asFound":"Abacavir","relevance":"HIGH"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"}]}},"hasResults":false}